Fig. 3

Expression levels of YAP1 are associated with progressive clinical characteristics and poor overall survival of PDAC patients. a-b, Representative images and statistical analyses of YAP1 expression in PDAC specimens from our cohort. Scale bars, 100 μm. Chi square test was used for statistical analysis. c, qRT-PCR analysis of YAP1 expression in TT and paired ANT specimens obtained from 12 PDAC patients. d, Results from TCGA database showed that expression of YAP1 mRNA in TT was significantly higher than that in ANT. Chi square test was used for statistical analysis. e, Staining score of YAP1 was positively assocaited with lymph node metastasis. Chi square test was used for statistical analysis. f-g, Kaplan-Meier analysis of overall survival of PDAC cases from our cohort (f; Log rank test, P = 0.003) and TCGA dataset (g; Log rank test, P = 0.025) according to expression of YAP1. Patients were grouped according to high and low YAP1 expression. TT, tumor tissues; ANT, adjacent non-cancerous tissues; PDAC, pancreatic ductal adenocarcinoma. GAPDH was used as an internal reference